# ISPOR 15<sup>th</sup> HTA Roundtable

Health Technology Assessment in Asia Wednesday, 5 September 2012

Grand Hyatt Taipei, Residence 2 (Lobby Level) 2 SongShou Road, Taipei, Taiwan 11051

# Organized by HTAnetAsia (AsiaNetHTA) of ISPOR Asia Consortium

#### **Moderators:**

Jie Chen, PhD, 2012-2014 Chair, ISPOR Asia Consortium HTA Agencies Committee, Director, Key Lab of Health Technology Assessment, Ministry of Health, Director, Center for Health Technology Assessment, Shanghai Municipal Bureau and Professor, School of Public Health, Fudan University, Shanghai, China Mainland

Yen-Huei (Tony) Tarn, MS, PhD, 2010-2012 Chair, ISPOR Asia Consortium HTA Agencies Committee, and Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

# **Speakers & Participants**

# NICE & HTA: Valuing New Health Technologies

Sir Andrew Dillon, Chief Executive, National Institute for Health and Clinical Excellence (NICE), London, UK

### HIRA & HTA: Drug Pricing and Reimbursement System in South Korea

Mi-young You, General Manager of Drug Listing Division, Health Insurance Review and Assessment Service (HIRA), Seoul, South Korea

Seung-Min Lee, Deputy Manager of Drug Listing Division, Health Insurance Review and Assessment Service (HIRA), Seoul, South Korea

Mi-hai Park, Associate Research Fellow of Drug Listing Division, Health Insurance Review and Assessment Service (HIRA), Seoul, South Korea

Bong-Min Yang, PhD, Professor, Health Economics, School of Public Health, Executive Director, Institute of Health and Environment, Seoul National University, and First-term President of Korean Association of Health Technology Assessment, Seoul, South Korea

#### CDE & HTA: Health Technology Assessment Experience from Taiwan

Raoh-Fang (Jasmine) Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

Mao-Ting Sheen, MSC, MA, Director, Department of Medical Review and Pharmaceutical Benefit, Bureau of National Health Insurance, Taipei, Taiwan

# WHO & HTA: HTA Education/Training Program in Asia

Jie Chen, PhD, Director, Key Lab of Health Technology Assessment, Ministry of Health, Director, Center for Health Technology Assessment, Shanghai Municipal Bureau and Professor, School of Public Health, Fudan University, Shanghai, China Mainland

#### ISPOR & HTA: HTA Roundtables and Health Care Decision-Maker Toolkit

Zandra Z. Yin, Director, International Development (Asia, Oceania, Europe and Africa), International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Nancy Sun, Assistant Manager, International Development (Asia, Oceania, Europe and Africa), ISPOR, Lawrenceville, NJ, USA

Robert Selby, Coordinator, International Development (Asia-Pacific), ISPOR, Lawrenceville, NJ, USA

#### **Overview: HTA Fast Growing in Asia**

Yen-Huei (Tony) Tarn, MS, PhD, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, and First-term Director of HTA Division, Center for Drug Evaluation, Taipei, Taiwan

### **HTA Recent Status in China Mainland**

Kejun Liu, PhD, Deputy Director, China National Health Development Research Center, Ministry of Health, Beijing, China Mainland

Shanlian Hu MD, MSc, Director, Center for Health Development Research, Shanghai Bureau of Health and Professor of Health Economics, School of Public Health, Fudan University, Shanghai, China

Haiying Wang, Secretary of Director, Center for Health Technology Assessment, Shanghai Municipal Bureau, Shanghai, China Mainland

Xiaojuan Yang, Associate Research Fellow, Center for Health Technology Assessment, Shanghai Municipal Bureau, Shanghai, China Mainland

# **HTA Recent Status in Japan**

Takashi Fukuda, PhD, Chief Senior Researcher, National Institute of Public Health, Saitama, Japan

# **HTA Recent Status in Kazakhstan**

Alexandr Kostyuk, MD, PhD, Head, Centre of Standardization and HTA, Republican Centre for Health Development, Astana, Kazakhstan

Alima Almadiyeva, MD, MSc, Senior Specialist in Health Technology Assessment, Centre of Standardization & HTA, Republican Centre for Health Development, Astana, Kazakhstan

# Pharmacoeconomic Requirement in Drug Listing Process in Malaysia

Faridah Aryani MD Yusof, PhD, Senior Principle Assistant Director, Ministry of Health, Petalingjava, Malaysia

# **HTA Recent Status in the Philippines**

Kenneth Hartigan-Go, MD, Director General, Food and Drug Administration, Muntinlupa City, Philippines